An investigation that the European Medicines Agency started this month into the risk of suicidal and self-harm thoughts when taking Novo Nordisk’s widely-used drugs for weight loss and type 2 diabetes – Saxenda (liraglutide), Wegovy (semaglutide) and Ozempic (semaglutide) – has been extended to include other GLP-1 receptor agonists.
Eli Lilly’s Trulicity (dulaglutide), AstraZeneca’s Byetta (exenatide) and Sanofi’s Lyxumia (lixisenatide) will now also be included in...